# Final Fix Report
**Generated:** 2026-03-23 13:29:37
**Status:** All 3 workers completed

---

## Worker Summary

### Worker 1 — Accuracy (factual_accuracy, severity_consistency, source_fidelity)
```
{
  "metadata": {
    "title": "Final Fix Pass — Accuracy Metrics",
    "date": "2026-03-23",
    "scope": "Three-target final fixes: CORR-006 adversarial failure, severity normalization, source attribution precision"
  },

  "factual_accuracy_score": {
    "score": 100,
    "basis": "10 of 10 corrections verified against source PDFs. CORR-006 adversarial failure resolved: the correction instruction contained an incorrect premise; the original rule E5-002 was factually accurate and has been retained with a confirming section_note. No inaccurate rule content remains in the corrected-rules files.",
    "issues_resolved": [
      {
        "id": "CORR-006",
        "prior_status": "Adversarial test FAILED — correction instruction incorrectly claimed ADME and receptor sensitivity are absent from Appendix A",
        "resolution": "Documented incorrect premise in correction instruction; confirmed Appendix A table does enumerate both items; original rule retained unchanged; section_note added with source page reference (pages 11-14) and disambiguation vs. Glossary (page 8)",
        "output_file": "final-fixes/accuracy/corr006-fixed.json"
      }
    ],
    "remaining_issues": []
  },

  "severity_score": {
    "score": 100,
    "basis": "All 18 rule files checked. 38 rules across 2 files normalized from non-standard scales to the 4-level standard (critical/high/medium/low). 4 files were already normalized. 12 files have no severity field (obligation or requirement-type fields preserved). 1 semantic exception documented (biotech-quality-rules.json uses 'severity' as obligation type, not gap severity — not modified, mapping documented for downstream aggregation).",
    "files_normalized": [
      {
        "file": "output-v2/regulations-crl/jurisdiction-divergences.json",
        "rules_normalized": 21,
        "mapping_applied": "aligned→low, moderate→medium, significant→high"
      },
      {
        "file": "output-v3/who-regs/japan-vs-fda-ema.json",
        "rules_normalized": 17,
        "mapping_applied": "HIGH→high, MEDIUM→medium, LOW→low; special case HIGH (for herbal/Kampo products)→high with context preserved in notes"
      }
    ],
    "invalid_severity_values_remaining": 0,
    "output_file": "final-fixes/accuracy/severity-audit.json"
  },

  "source_fidelity_score": {
    "score": 100,
    "basis": "All 8 annotated references upgraded from corpus-level annotations to precise statutory citations. 7 references now carry full Public Law numbers, Statutes at Large references, enactment dates, codification locations, and CFR implementation pointers. 1 reference (state pharmacy laws) has an acknowledged inherent limitation (state law varies across 50 jurisdictions) — the federal framework is fully cited and representative state examples added.",
    "references_upgraded": 8,
    "precision_improvements": {
      "public_law_numbers_added": 6,
      "stat_references_added": 6,
      "cfr_implementation_pointers_added": 8,
      "source_page_numbers_added": 7,
      "fda_guidance_cross_references_added": 5,
      "limitation_acknowledged_and_documented": 1
    },
    "residual_risk": "none for 7/8 references; low for DIV-041 (state pharmacy laws — inherent jurisdiction variation, cannot be eliminated without 50-state corpus)",
    "output_file": "final-fixes/accuracy/source-precision.json"
  },

  "overall_assessment": {
    "target_factual_accuracy": 100,
    "achieved_factual_accuracy": 100,
    "target_severity_consistency": 100,
```

### Worker 2 — eCTD Mapping (ectd_module_consistency)
```
{
  "meta": {
    "title": "eCTD Module Mapping Corrections",
    "authority": "ICH M4(R4) Organisation of the Common Technical Document — Step 4, June 15, 2016",
    "generated": "2026-03-23",
    "version": "1.0",
    "scope": "All rule JSON files from output-v2/ and output-v3/; corrections verified against M4(R4) Tables 1-6 (Granularity Document)"
  },

  "ctd_module_reference": {
    "note": "Definitive ICH M4(R4) CTD structure — use this as ground truth for all eCTD module assignments",
    "module_1": {
      "title": "Administrative Information and Prescribing Information",
      "note": "Region-specific. Content and sub-sections defined by each regulatory authority (FDA, EMA, PMDA, Health Canada). Sub-sections below 1.1/1.2 are NOT harmonized and MUST be labeled as region-specific.",
      "harmonized_sections": ["1.1 Table of Contents", "1.2 Documents Specific to Each Region"],
      "fda_specific": ["1.3.1 Patent Certifications", "1.5 Environmental Assessment", "1.8 User Fees", "1.12 Debarment Certification", "1.14 Labeling", "1.18 Pediatric Administrative Information"],
      "ema_specific": ["1.2 Application Form", "1.3 Product Information", "1.6 Environmental Risk Assessment"]
    },
    "module_2": {
      "title": "Common Technical Document Summaries",
      "sections": {
        "2.1": "CTD Table of Contents (Modules 2-5)",
        "2.2": "CTD Introduction",
        "2.3": "Quality Overall Summary (QOS)",
        "2.3.S": "Drug Substance QOS (mirrors 3.2.S subsections: S.1-S.7)",
        "2.3.P": "Drug Product QOS (mirrors 3.2.P subsections: P.1-P.8)",
        "2.3.A": "QOS Appendices (A.1 Facilities, A.2 Adventitious Agents, A.3 Excipients)",
        "2.3.R": "Regional Information",
        "2.4": "Nonclinical Overview (narrative critical analysis of nonclinical program)",
        "2.5": "Clinical Overview (narrative critical analysis of clinical program)",
        "2.6": "Nonclinical Written and Tabulated Summaries",
        "2.6.1": "Introduction (Pharmacology)",
        "2.6.2": "Pharmacology Written Summary (primary PD, secondary PD, safety pharmacology, PD interactions)",
        "2.6.3": "Pharmacology Tabulated Summary",
        "2.6.4": "Pharmacokinetics Written Summary",
        "2.6.5": "Pharmacokinetics Tabulated Summary",
        "2.6.6": "Toxicology Written Summary",
        "2.6.7": "Toxicology Tabulated Summary",
        "2.7": "Clinical Summary",
        "2.7.1": "Summary of Biopharmaceutics Studies and Associated Analytical Methods",
        "2.7.2": "Summary of Clinical Pharmacology Studies",
        "2.7.3": "Summary of Clinical Efficacy",
        "2.7.4": "Summary of Clinical Safety",
        "2.7.5": "Literature References",
        "2.7.6": "Synopses of Individual Studies"
      }
    },
    "module_3": {
      "title": "Quality",
      "sections": {
        "3.1": "Table of Contents",
        "3.2": "Body of Data",
        "3.2.S": "Drug Substance",
        "3.2.S.1": "General Information (nomenclature, structure, properties)",
        "3.2.S.2": "Manufacture (manufacturer, process, controls, validation)",
        "3.2.S.3": "Characterisation (structure/elucidation, impurity profiling — NOT analytical procedures for control)",
        "3.2.S.4": "Control of Drug Substance (specifications, analytical procedures, validation, batch analysis, justification)",
        "3.2.S.5": "Reference Standards or Materials",
        "3.2.S.6": "Container Closure System",
        "3.2.S.7": "Stability (drug substance stability data)",
```

### Worker 3 — Safety Pharmacology (safety_pharmacology)
```
{
  "meta": {
    "title": "ICH Safety Pharmacology & Nonclinical Timing Rules",
    "sources": [
      "ICH S7A — Safety Pharmacology Studies for Human Pharmaceuticals (Nov 2000)",
      "ICH S7B — Nonclinical Evaluation of the Potential for Delayed Ventricular Repolarization (May 2005)",
      "ICH M3(R2) — Guidance on Nonclinical Safety Studies for Clinical Trials and Marketing Authorization (Jun 2009)",
      "ICH E14/S7B Q&As (Feb 2022)",
      "ICH M3(R2) Q&As R2 (Mar 2012)",
      "ICH E14/S7B IWG Concept Papers (2018, 2024)"
    ],
    "version": "2.0.0-verified",
    "extracted": "2026-03-22",
    "verified": "2026-03-23",
    "verification_method": "Systematic section-by-section check against source PDFs: S7A (all 13 pages), S7B (all 14 pages), E14/S7B Q&As (all 46 pages), E14 (all pages). All changes documented in changes-made.json."
  },

  "definitions": {
    "safety_pharmacology": "Studies that investigate the potential undesirable pharmacodynamic effects of a substance on physiological functions in relation to exposure in the therapeutic range and above.",
    "source_verified": "S7A Section 1.5 (page 1 of guideline): 'safety pharmacology studies are defined as those studies that investigate the potential undesirable pharmacodynamic effects of a substance on physiological functions in relation to exposure in the therapeutic range and above.' CONFIRMED ACCURATE.",
    "primary_pharmacodynamics": "Studies on the mode of action and/or effects in relation to the desired therapeutic target.",
    "primary_pharmacodynamics_source_verified": "S7A Section 3 Note 2 (page 8 of guideline): 'Studies on the mode of action and/or effects of a substance in relation to its desired therapeutic target are primary pharmacodynamic studies.' CONFIRMED ACCURATE.",
    "secondary_pharmacodynamics": "Studies on the mode of action and/or effects not related to the desired therapeutic target.",
    "secondary_pharmacodynamics_source_verified": "S7A Section 3 Note 2 (page 8 of guideline): 'Studies on the mode of action and/or effects of a substance not related to its desired therapeutic target are secondary pharmacodynamic studies.' CONFIRMED ACCURATE.",
    "core_battery": "Safety pharmacology studies designed to investigate effects on vital organ functions (cardiovascular, central nervous, respiratory systems). Required before first administration in humans.",
    "core_battery_source_verified": "S7A Section 2.7 (page 5): 'The purpose of the safety pharmacology core battery is to investigate the effects of the test substance on vital functions. In this regard, the cardiovascular, respiratory and central nervous systems are usually considered the vital organ systems that should be studied in the core battery.' CONFIRMED ACCURATE.",
    "follow_up_studies": "Studies designed to provide greater depth of understanding of effects observed or suspected from core battery, clinical, pharmacovigilance, or literature data. Conducted on a case-by-case basis.",
    "follow_up_studies_source_verified": "S7A Section 2.8.1 (page 5): 'Follow-up studies are meant to provide a greater depth of understanding than, or additional knowledge to, that provided by the core battery on vital functions.' CONFIRMED ACCURATE.",
    "supplemental_studies": "Studies evaluating effects on organ systems not addressed by the core battery (renal/urinary, autonomic nervous, gastrointestinal, and other organ systems).",
    "supplemental_studies_source_verified": "S7A Section 2.8.2 (page 6): 'Supplemental studies are meant to evaluate potential adverse pharmacodynamic effects on organ system functions not addressed by the core battery or repeated dose toxicity studies when there is a cause for concern.' CONFIRMED ACCURATE.",
    "hERG_safety_margin": "Ratio of hERG IC50 (free drug concentration) to estimated clinically relevant free drug exposure; used to predict risk of delayed ventricular repolarization.",
    "hERG_safety_margin_source_verified": "E14/S7B Q&A 1.2 (page 29): 'A drug's potency for hERG block, usually calculated as half-inhibitory concentration (IC50), can be normalized to the drug's estimated clinically relevant exposures in patients to calculate the safety margin.' CONFIRMED ACCURATE. Note: the specific formula (free IC50/free Cmax,ss) is further detailed in Q&A 1.2 as the recommended approach.",
    "integrated_risk_assessment": "Combined evaluation of nonclinical (in vitro hERG, in vivo QT, follow-up studies) and clinical (QTc, concentration-response, ECG monitoring) data to determine proarrhythmic risk.",
    "integrated_risk_assessment_source_verified": "S7B Section 2.3.6 (page 6 of S7B): 'The integrated risk assessment is the evaluation of non-clinical study results including the results from follow-up studies and other relevant information.' E14/S7B Q&A 1.1 (page 27) provides fuller contemporary framework. CONFIRMED ACCURATE.",
    "thorough_QT_study": "Dedicated clinical study (ICH E14) designed to determine whether a drug has threshold pharmacologic effect on cardiac repolarization (QT/QTc prolongation).",
    "thorough_QT_study_source_verified": "E14 Section 2.2 (page 3 of guideline): 'The thorough QT/QTc study is intended to determine whether the drug has a threshold pharmacologic effect on cardiac repolarization, as detected by QT/QTc prolongation.' CONFIRMED ACCURATE."
  },

  "scope": {
    "applies_to": [
      "New chemical entities",
      "Biotechnology-derived products (with modifications per ICH S6)",
      "Marketed pharmaceuticals (when new indications, routes, populations, or formulations warrant)"
    ],
    "applies_to_source_verified": "S7A Section 1.3 (page 1): 'This guideline generally applies to new chemical entities and biotechnology-derived products for human use. This guideline can be applied to marketed pharmaceuticals when appropriate (e.g., when adverse clinical events, a new patient population, or a new route of administration raises concerns not previously addressed).' CONFIRMED ACCURATE.",
    "out_of_scope": [
      "Excipients evaluated within existing formulations",
      "Herbal/traditional medicines (unless subject to ICH region regulations)"
    ],
    "out_of_scope_note": "PARTIALLY VERIFIED. S7A Section 2.9 (page 6) lists specific conditions under which studies are not necessary (locally applied agents with low systemic exposure; cytotoxic agents for end-stage cancer; biotechnology-derived products with high target specificity; new salts with similar PK/PD). The out_of_scope items for excipients and herbal medicines are reasonable inferences consistent with S7A's scope statement but are not explicitly enumerated in S7A. S7A Section 2.6 addresses finished product formulations only when they 'substantially alter the pharmacokinetics and/or pharmacodynamics.' This item carries verification_status: PARTIALLY_VERIFIED — consistent with S7A but not directly quoted.",
    "verification_status_out_of_scope": "PARTIALLY_VERIFIED",
    "modality_considerations": {
      "small_molecules": "Full S7A core battery + S7B hERG/in vivo QT required",
      "small_molecules_source_verified": "S7A Section 1.3 and S7B Section 1.3 apply to new chemical entities. CONFIRMED ACCURATE.",
      "monoclonal_antibodies": "Low likelihood of direct ion channel interaction; TQT study not necessary unless target-related cardiac repolarization risk exists [E14 Q&A 6.3]. Reduced safety pharmacology package may be appropriate for highly target-specific biotechnology-derived products [ICH S6(R1)].",
      "monoclonal_antibodies_source_document": "E14/S7B Q&A 6.3 (March 2014, page 22): 'Large targeted proteins and monoclonal antibodies have a low likelihood of direct ion channel interactions and a thorough QT/QTc study is not necessary, unless the potential for proarrhythmic risk is suggested by mechanistic considerations or data from clinical or non-clinical studies.' NOTE: This rule was originally presented without clear source annotation. The TQT waiver is sourced to E14 Q&A 6.3, NOT to ICH S7B (2005). ICH S7B (2005) does not address mAbs specifically. ICH S6(R1) provides the basis for reduced safety pharmacology in highly target-specific biotechnology products.",
      "monoclonal_antibodies_source_verified": "E14 Q&A 6.3 confirmed on page 22 of E14/S7B Q&As PDF. Text reproduced verbatim above. CORRECTION APPLIED per CORR-005.",
      "large_targeted_proteins": "Same as monoclonal antibodies per E14 Q&A 6.3",
      "large_targeted_proteins_source_verified": "E14 Q&A 6.3 (page 22): 'Large targeted proteins and monoclonal antibodies have a low likelihood of direct ion channel interactions...' CONFIRMED ACCURATE.",
      "antibody_drug_conjugates": "Assess based on both antibody and small molecule payload properties",
```

---

## Before/After Scores by Dimension

| Dimension | Before | After | Target | Status |
|-----------|--------|-------|--------|--------|
| factual_accuracy | (see worker output) | 100 | 100 | ✓ |
| severity_consistency | (see worker output) | 100 | 100 | ✓ |
| ectd_module_consistency | (see worker output) | 15 | 100 | ⚠ BELOW THRESHOLD |
| source_fidelity | (see worker output) | 100 | 100 | ✓ |
| safety_pharmacology | (see worker output) | 200 | 100 | ✓ |

---

## Flags

  ⚠ ectd_module_consistency: 15 < 98 (BELOW THRESHOLD — FLAG FOR REVIEW)

---

## Adversarial Testing Readiness

🚫 **HOLD** — one or more dimensions below threshold or failed to parse. Review flags above before proceeding.
